Multimodal data fusion for cancer biomarker discovery with deep learning
Technological advances have made it possible to study a patient from multiple angles with
high-dimensional, high-throughput multiscale biomedical data. In oncology, massive …
high-dimensional, high-throughput multiscale biomedical data. In oncology, massive …
An overview of real‐world data sources for oncology and considerations for research
LT Penberthy, DR Rivera, JL Lund… - CA: A Cancer …, 2022 - Wiley Online Library
Generating evidence on the use, effectiveness, and safety of new cancer therapies is a
priority for researchers, health care providers, payers, and regulators given the rapid pace of …
priority for researchers, health care providers, payers, and regulators given the rapid pace of …
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …
Evaluating eligibility criteria of oncology trials using real-world data and AI
There is a growing focus on making clinical trials more inclusive but the design of trial
eligibility criteria remains challenging,–. Here we systematically evaluate the effect of …
eligibility criteria remains challenging,–. Here we systematically evaluate the effect of …
Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR
ABSTRACT Background and Objective The Surveillance, Epidemiology, and End Results
Program (SEER) program and the National Program of Cancer Registries (NPCR), are …
Program (SEER) program and the National Program of Cancer Registries (NPCR), are …
[HTML][HTML] Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer
D Waterhouse, J Lam, KA Betts, L Yin, S Gao, Y Yuan… - Lung Cancer, 2021 - Elsevier
Abstract Background First-line (1L) immunotherapy (IO) has improved outcomes in patients
with advanced non-small cell lung cancer (NSCLC) in clinical trials and is now routinely …
with advanced non-small cell lung cancer (NSCLC) in clinical trials and is now routinely …
Precision medicine: affording the successes of science
Science has made remarkable advances in understanding the molecular basis of disease,
generating new and effective rationally-designed treatments at an accelerating rate …
generating new and effective rationally-designed treatments at an accelerating rate …
[HTML][HTML] Immunotherapy in non-small cell lung cancer: Update and new insights
X Mielgo-Rubio, EA Uribelarrea, LQ Cortés… - Journal of clinical and …, 2021 - ncbi.nlm.nih.gov
Background: The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
V Velcheti, X Hu, B Piperdi, T Burke - Scientific reports, 2021 - nature.com
Evidence from real-world clinical settings is lacking with regard to first-line immunotherapy
plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to …
plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to …
Tailoring therapy for children with neuroblastoma on the basis of risk group classification: past, present, and future
For children with neuroblastoma, the likelihood of cure varies widely according to age at
diagnosis, disease stage, and tumor biology. Treatments are tailored for children with this …
diagnosis, disease stage, and tumor biology. Treatments are tailored for children with this …